Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

Trial Profile

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Focal segmental glomerulosclerosis; IgA nephropathy; Renal failure
  • Focus Therapeutic Use
  • Acronyms PHOENIX
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2019 According to a Reata Pharmaceuticals media release, data presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting.
    • 07 Nov 2018 According to a Reata Pharmaceuticals media release, Final 12-week data from the FSGS cohort is expected in the first half of 2019.
    • 16 Oct 2018 According to a Reata Pharmaceuticals media release, data will be presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top